Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALIGN TECHNOLOGY INCALGN · Entity 3488 | Director | August 27, 2026 | August 31, 2026 |
| Alphatec Holdings, Inc.ATEC · Entity 4720 | Director | June 10, 2026 | June 12, 2026 |
| DEXCOM INCDXCM · Entity 3114 | Chief Operating Officer | September 08, 2021 | September 10, 2021 |
| NUVASIVE INCNUVA · Entity 110002 | CFO | February 08, 2017 | February 10, 2017 |
| iRhythm Holdings, Inc.IRTC · Entity 1499 | Director · President and CEO | August 07, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALIGN TECHNOLOGY INC
Report date August 27, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,376 |
Reported balance
After 2026-08-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-27 · Grant · Acquired 1,376 · Balance 1,376 F1: 100% of the RSUs granted on August 27, 2026 will become vested on the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the RSUs granted on August 27, 2026 will become vested on the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date.
Alphatec Holdings, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 600,381 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 32,012 · Balance 600,381 F1: On June 10, 2026, issuer granted to the reporting person 32,012 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rata based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, issuer granted to the reporting person 32,012 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rata based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365.
DEXCOM INC
Report date September 08, 2021 · Filed September 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,280 |
Last balance in matching sequence
After 2021-09-10 transaction · row 14
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
14 source rowsRow 1 · 2021-09-08 · Sale · Disposed 7,639 · Balance 30,303 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 2 · 2021-09-08 · Sale · Disposed 42 · Balance 30,261 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 3 · 2021-09-09 · Sale · Disposed 1,534 · Balance 28,727 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 4 · 2021-09-09 · Sale · Disposed 19 · Balance 28,708 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 5 · 2021-09-09 · Sale · Disposed 515 · Balance 28,193 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $541.36 to $541.79. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 6 · 2021-09-09 · Sale · Disposed 300 · Balance 27,893 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5: This transaction was executed in multiple trades at prices ranging from $542.55 to $543.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 7 · 2021-09-09 · Sale · Disposed 100 · Balance 27,793 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 8 · 2021-09-09 · Sale · Disposed 100 · Balance 27,693 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 9 · 2021-09-09 · Sale · Disposed 900 · Balance 26,793 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6: This transaction was executed in multiple trades at prices ranging from $546.75 to $547.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 10 · 2021-09-09 · Sale · Disposed 1,200 · Balance 25,593 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7: This transaction was executed in multiple trades at prices ranging from $547.885 to $548.790. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 11 · 2021-09-09 · Sale · Disposed 2,394 · Balance 23,199 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8: This transaction was executed in multiple trades at prices ranging from $548.93 to $549.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 12 · 2021-09-09 · Sale · Disposed 2,200 · Balance 20,999 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9: This transaction was executed in multiple trades at prices ranging from $549.95 to $550.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 13 · 2021-09-09 · Sale · Disposed 200 · Balance 20,799 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10: This transaction was executed in multiple trades at prices ranging from $551.15 to $551.42. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Row 14 · 2021-09-10 · Sale · Disposed 1,519 · Balance 19,280 F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 19,047 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,072 of which were granted on March 8, 2019 and shall vest through March 8, 2022.
F3: On February 17, 2021 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F4: This transaction was executed in multiple trades at prices ranging from $541.36 to $541.79. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F5: This transaction was executed in multiple trades at prices ranging from $542.55 to $543.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F6: This transaction was executed in multiple trades at prices ranging from $546.75 to $547.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F7: This transaction was executed in multiple trades at prices ranging from $547.885 to $548.790. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F8: This transaction was executed in multiple trades at prices ranging from $548.93 to $549.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F9: This transaction was executed in multiple trades at prices ranging from $549.95 to $550.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F10: This transaction was executed in multiple trades at prices ranging from $551.15 to $551.42. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
NUVASIVE INC
Report date February 08, 2017 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PRSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 13,203 |
Reported balance
After 2017-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-08 · Grant · Acquired 13,203 · Balance 13,203 F1: Each performance restricted stock unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: This PRSU award was granted to the Reporting Person on March 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on March 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance restricted stock unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: This PRSU award was granted to the Reporting Person on March 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on March 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant.
iRhythm Holdings, Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 226,008 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-07 · Grant · Acquired 48,534 · Balance 252,867 F1: Represents the acquisition of shares upon the determination of the Compensation & Human Capital Management Committee of the Board of Directors of the Issuer that the performance conditions were met with respect to performance Restricted Stock Units ("RSUs") granted to the Reporting Person on August 7, 2023. Row 2 · 2026-08-10 · Sale · Disposed 26,859 · Balance 226,008 F2: These shares were sold to cover tax withholding and remittance obligations in connection with the vesting of performance RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the acquisition of shares upon the determination of the Compensation & Human Capital Management Committee of the Board of Directors of the Issuer that the performance conditions were met with respect to performance Restricted Stock Units ("RSUs") granted to the Reporting Person on August 7, 2023.
F2: These shares were sold to cover tax withholding and remittance obligations in connection with the vesting of performance RSUs.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date March 30, 2022 · Filed April 01, 2022
Section 16 reporting ended · disclosed 2022-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,335 |
Reported balance
After 2022-03-30 transaction · row 1
1 source rowRow 1 · 2022-03-30 · Exercise / conversion · Acquired 3,036 · Balance 27,335 F1: This reflects the number of restricted stock units that became vested as of March 30, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-30 · Exercise / conversion · Disposed 3,036 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. This grant was accelerated by Axogen's Board of Directors to vest upon departure. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that became vested as of March 30, 2022.
F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F3: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. This grant was accelerated by Axogen's Board of Directors to vest upon departure.
Paragon 28, Inc.
Report date April 21, 2025 · Filed April 21, 2025
Section 16 reporting ended · disclosed 2025-04-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 1
1 source rowRow 1 · 2025-04-21 · Disposition to issuer · Disposed 50,554 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the "Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. ("Parent"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor. F3: At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the "Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. ("Parent"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor.
F3: At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 457 | $223.62 | $102,195.80 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 7 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,116 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $223.40 to $223.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $220.50 | $44,100.00 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 6 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,573 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $219.37 | $43,873.00 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 5 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,773 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $219.33 to $219.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 12, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 583 | $218.84 | $127,582.32 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 4 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,973 F4 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $218.51 to $219. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,963 | $265.43 | $1,582,735.24 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 3 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,556 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 129 | $251.03 | $32,382.64 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,519 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 116 | $246.61 | $28,606.70 |
DisclosureSEC source: 0001093557-20-000094 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,648 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $246.00 to $246.62. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 891 | $261.00 | $232,551.00 |
DisclosureSEC source: 0001093557-20-000077 · edgardoc.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,764 F3 · shares: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 08, 2020 Filed Mar 11, 2020 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 12,727 | $0.00 | $12.73 |
DisclosureSEC source: 0001093557-20-000077 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,655 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $144.57 | $86,741.52 |
DisclosureSEC source: 0001093557-19-000203 · edgardoc.xml · nonDerivative · entry 6 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,754 F1 · shares: On February 27, 2019 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $144.33 to $144.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 68,863 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 406 | $143.57 | $58,288.28 |
DisclosureSEC source: 0001093557-19-000203 · edgardoc.xml · nonDerivative · entry 5 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,354 F1 · shares: On February 27, 2019 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $143.15 to $143.80. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 68,863 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,289 | $142.16 | $183,246.69 |
DisclosureSEC source: 0001093557-19-000203 · edgardoc.xml · nonDerivative · entry 4 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,760 F1 · shares: On February 27, 2019 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $142.01 to $143. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 68,863 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,725 | $141.62 | $527,517.37 |
DisclosureSEC source: 0001093557-19-000203 · edgardoc.xml · nonDerivative · entry 3 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,049 F1 · shares: On February 27, 2019 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $141.00 to $141.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 68,863 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,500 | $140.47 | $351,181.00 |
DisclosureSEC source: 0001093557-19-000203 · edgardoc.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,774 F1 · shares: On February 27, 2019 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $140.00 to $140.98. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 68,863 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,800 | $139.29 | $250,716.42 |
DisclosureSEC source: 0001093557-19-000203 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,274 F1 · shares: On February 27, 2019 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $139.00 to $139.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 68,863 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 11,049 | $150.11 | $1,658,577.54 |
DisclosureSEC source: 0001093557-19-000199 · edgardoc.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,074 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 68,863 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 637 | $145.45 | $92,654.20 |
DisclosureSEC source: 0001093557-19-000199 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,123 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $145.41 to $145.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 68,863 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010129 · edgar.xml · derivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-19-010129 · edgar.xml · derivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 12:45 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 14,170 | $14.10 | $199,797.00 |
DisclosureSEC source: 0001179110-19-009405 · edgar.xml · nonDerivative · entry 3 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,468 Read SEC document |
| August 12, 2019 Filed Jun 5, 2020 20:48 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 14,170 | $14.10 | $199,797.00 |
DisclosureSEC source: 0001179110-20-007033 · edgar.xml · nonDerivative · entry 3 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,535 F1 · balance_after: The original Form 4 filed on August 13, 2019 incorrectly stated, in Column 5, the total number of shares beneficially owned by the Reporting Person. This Form 4/A is being filed to correct the error. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 12:45 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 200 | $13.07 | $2,614.00 |
DisclosureSEC source: 0001179110-19-009405 · edgar.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,298 Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 12:45 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 1,165 | $13.10 | $15,261.50 |
DisclosureSEC source: 0001179110-19-009405 · edgar.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,098 Read SEC document |
| August 09, 2019 Filed Jun 5, 2020 20:48 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 200 | $13.07 | $2,614.00 |
DisclosureSEC source: 0001179110-20-007033 · edgar.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,365 F1 · balance_after: The original Form 4 filed on August 13, 2019 incorrectly stated, in Column 5, the total number of shares beneficially owned by the Reporting Person. This Form 4/A is being filed to correct the error. Read SEC document |
| August 09, 2019 Filed Jun 5, 2020 20:48 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 1,165 | $13.10 | $15,261.50 |
DisclosureSEC source: 0001179110-20-007033 · edgar.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,165 F1 · balance_after: The original Form 4 filed on August 13, 2019 incorrectly stated, in Column 5, the total number of shares beneficially owned by the Reporting Person. This Form 4/A is being filed to correct the error. Read SEC document |
| June 21, 2019 Filed Jun 25, 2019 21:45 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 18,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008105 · edgar.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502,167 F1 · date: On June 21, 2019, issuer granted to the reporting person 18,086 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · date: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. F1 · shares: On June 21, 2019, issuer granted to the reporting person 18,086 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · shares: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. F1 · balance_after: On June 21, 2019, issuer granted to the reporting person 18,086 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · balance_after: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. Read SEC document |
| May 29, 2019 Filed May 30, 2019 20:56 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,376 | $119.30 | $402,761.53 |
DisclosureSEC source: 0001093557-19-000134 · edgardoc.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,740 F1 · shares: On February 27, 2019 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $119.18 to $119.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 90,869 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 46,769 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| May 29, 2019 Filed May 30, 2019 20:56 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,498 | $118.73 | $652,765.44 |
DisclosureSEC source: 0001093557-19-000134 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,116 F1 · shares: On February 27, 2019 Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $118.18 to $119.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 90,869 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 46,769 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| May 15, 2019 Filed May 18, 2019 01:38 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 23,933 | $0.00 Strike: $22.99 | $0.00 |
DisclosureSEC source: 0001179110-19-006341 · edgar.xml · derivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,933 Underlying: Common Stock · 23,933 shares Expires 2022-05-15 F1 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest annually in equal parts over a three year period and become fully vested on May 15, 2022. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,358 | $142.79 | $765,080.61 |
DisclosureSEC source: 0001093557-19-000079 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,614 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 90,869 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 46,769 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 00:40 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 18,432 | $0.00 | $18.43 |
DisclosureSEC source: 0001093557-19-000057 · wf-form4_155235122046206.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,972 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 90,869 unvested restricted stock units, 18,432 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 46,769 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 11, 2018 Filed Sep 14, 2018 01:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,680 | $148.22 | $545,453.65 |
DisclosureSEC source: 0000899243-18-024485 · doc4.xml · nonDerivative · entry 4 Blackford Quentin S. · CIK 0001612451 · EVP, CFO, PFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,131 F1 · shares: On August 7, 2018, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $147.75 to $148.44. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 85,271 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 46,769 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 11, 2018 Filed Sep 14, 2018 01:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,460 | $147.41 | $215,213.49 |
DisclosureSEC source: 0000899243-18-024485 · doc4.xml · nonDerivative · entry 3 Blackford Quentin S. · CIK 0001612451 · EVP, CFO, PFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,811 F1 · shares: On August 7, 2018, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $146.75 to $147.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 85,271 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 46,769 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 11, 2018 Filed Sep 14, 2018 01:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,200 | $146.15 | $175,377.96 |
DisclosureSEC source: 0000899243-18-024485 · doc4.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · EVP, CFO, PFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,271 F1 · shares: On August 7, 2018, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $145.68 to $146.58. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 85,271 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 46,769 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 11, 2018 Filed Sep 14, 2018 01:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,100 | $145.23 | $304,982.58 |
DisclosureSEC source: 0000899243-18-024485 · doc4.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · EVP, CFO, PFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,471 F1 · shares: On August 7, 2018, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $144.54 to $145.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 85,271 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 46,769 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,149 | $143.76 | $1,027,705.92 |
DisclosureSEC source: 0001093557-18-000193 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · EVP, CFO, PFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,571 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 85,271 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 46,769 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| July 30, 2018 Filed Aug 2, 2018 00:29 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 21,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-010074 · edgar.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,081 F3 · date: On July 30, 2018, issuer granted to the reporting person 21,111 restricted stock units, which vested immediately upon grant. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F3 · shares: On July 30, 2018, issuer granted to the reporting person 21,111 restricted stock units, which vested immediately upon grant. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F3 · balance_after: On July 30, 2018, issuer granted to the reporting person 21,111 restricted stock units, which vested immediately upon grant. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. Read SEC document |
| July 30, 2018 Filed Aug 2, 2018 00:29 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 20,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-010074 · edgar.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,970 F1 · date: On July 30, 2018, issuer granted to the reporting person 20,492 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · date: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. F1 · shares: On July 30, 2018, issuer granted to the reporting person 20,492 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · shares: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. F1 · balance_after: On July 30, 2018, issuer granted to the reporting person 20,492 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · balance_after: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 01:34 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 38,502 | $0.00 | $38.50 |
DisclosureSEC source: 0001093557-18-000039 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · EVP, CFO, PFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,258 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 100,860 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 62,358 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| December 28, 2017 Filed Dec 29, 2017 19:37 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 442,478 | $2.26 | $1,000,000.28 |
DisclosureSEC source: 0001179110-17-015933 · edgar.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,478 F1 · kind: Purchase made pursuant to that certain Securities Purchase Agreement, dated October 2, 2017, by and between the Company and Reporting Person, as disclosed by the Company on SEC Current Report on Form 8-K, filed October 2, 2017. F1 · price: Purchase made pursuant to that certain Securities Purchase Agreement, dated October 2, 2017, by and between the Company and Reporting Person, as disclosed by the Company on SEC Current Report on Form 8-K, filed October 2, 2017. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 23:47 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 62,358 | $0.00 | $62.36 |
DisclosureSEC source: 0001093557-17-000185 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · EVP, CFO, PFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,756 F1 · shares: Represents a grant of restricted stock units that shall vest in four equal annual installments on September 7, 2018, September 7, 2019, September 7, 2020 and September 7, 2021. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 62,358 unvested restricted stock units which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 17:44 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 13,203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009677 · doc4.xml · derivative · entry 1 Blackford Quentin S. · CIK 0001612451 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,203 Underlying: Common Stock · 13,203 shares Expires not disclosed F1 · security: Each performance restricted stock unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on March 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on March 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:50 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 3,192 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007772 · doc4.xml · derivative · entry 5 Blackford Quentin S. · CIK 0001612451 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,384 Underlying: Common Stock · 3,192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F6 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the PRSU award, the award vested as to 3,193 shares on February 1, 2016, vested as to 3,192 shares on February 1, 2017, and will vest as to 3,192 shares on each of February 1, 2018 and February 1, 2019. F6 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the PRSU award, the award vested as to 3,193 shares on February 1, 2016, vested as to 3,192 shares on February 1, 2017, and will vest as to 3,192 shares on each of February 1, 2018 and February 1, 2019. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:50 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 5,339 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007772 · doc4.xml · derivative · entry 4 Blackford Quentin S. · CIK 0001612451 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,339 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on February 26, 2013. In accordance with the terms of the RSU award, the award vested as to 5,340 shares on February 1, 2014, and vested as to 5,339 shares on each of February 1, 2015, February 1, 2016 and February 1, 2017. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on February 26, 2013. In accordance with the terms of the RSU award, the award vested as to 5,340 shares on February 1, 2014, and vested as to 5,339 shares on each of February 1, 2015, February 1, 2016 and February 1, 2017. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:50 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 3,266 | $70.76 | $231,102.16 |
DisclosureSEC source: 0001209191-17-007772 · doc4.xml · nonDerivative · entry 3 Blackford Quentin S. · CIK 0001612451 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,004 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:50 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 3,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007772 · doc4.xml · nonDerivative · entry 2 Blackford Quentin S. · CIK 0001612451 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:50 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 5,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007772 · doc4.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 18:00 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 5,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001323 · doc4.xml · derivative · entry 5 Blackford Quentin S. · CIK 0001612451 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,924 Underlying: Common Stock · 5,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on January 26, 2014. In accordance with the terms of the RSU award, the award vested as to 5,925 shares on January 1, 2015, vested as to 5,924 shares on each of January 1, 2016 and January 1, 2017, and will vest as to 5,924 shares on January 1, 2018. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on January 26, 2014. In accordance with the terms of the RSU award, the award vested as to 5,925 shares on January 1, 2015, vested as to 5,924 shares on each of January 1, 2016 and January 1, 2017, and will vest as to 5,924 shares on January 1, 2018. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 18:00 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 3,593 | $67.36 | $242,024.48 |
DisclosureSEC source: 0001209191-17-001323 · doc4.xml · nonDerivative · entry 4 Blackford Quentin S. · CIK 0001612451 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,739 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 18:00 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 5,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001323 · doc4.xml · nonDerivative · entry 3 Blackford Quentin S. · CIK 0001612451 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.